Literature DB >> 14609573

Memory and effector T cells modulate subsequently primed immune responses to unrelated antigens.

Jide Tian1, Yuxin Lu, Lorraine Hanssen, Hoa Dang, Daniel L Kaufman.   

Abstract

Memory and effector T cells modulate subsequently primed T cell responses to the same antigen. However, little is known about the impact of pre-existing memory and effector T cell immunity on subsequently primed immune responses to unrelated antigens. Here, we show that an antigen-primed first wave of Th1 and Th2 immunity enhanced or inhibited the subsequently primed T cell immunity to an unrelated antigen, depending on whether the second antigen was administered in the same or opposite type of adjuvant. The regulatory effects of the first wave of T cell immunity on the subsequent T cell responses to an unrelated antigen attenuated over time. Notably, following challenge with the second antigen, there was a mutual cross-regulation between the first and second wave of humoral responses to unrelated antigens. Thus, immunization with one antigen not only primes immune responses to that antigen, but also influences subsequently primed immune responses to unrelated antigens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14609573     DOI: 10.1016/j.cellimm.2003.08.007

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

1.  The postnatal maternal environment influences diabetes development in nonobese diabetic mice.

Authors:  L R Washburn; H Dang; J Tian; D L Kaufman
Journal:  J Autoimmun       Date:  2007-01-04       Impact factor: 7.094

2.  Designing Personalized Antigen-Specific Immunotherapies for Autoimmune Diseases-The Case for Using Ignored Target Cell Antigen Determinants.

Authors:  Jide Tian; Min Song; Daniel L Kaufman
Journal:  Cells       Date:  2022-03-23       Impact factor: 6.600

3.  Antigen-based therapy for the treatment of type 1 diabetes.

Authors:  Jide Tian; Daniel L Kaufman
Journal:  Diabetes       Date:  2009-09       Impact factor: 9.461

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.